Tüzmen Ş - Search Results

1

Characterization of farnesyl diphosphate farnesyl transferase 1 (FDFT1) expression in cancer.

Tüzmen Ş, Hostetter G, Watanabe A, Ekmekçi C, Carrigan PE, Shechter I, Kallioniemi O, Miller LJ, Mousses S. Tüzmen Ş, et al. Per Med. 2019 Jan;16(1):51-65. doi: 10.2217/pme-2016-0058. Epub 2018 Nov 23. Per Med. 2019. PMID: 30468409

2

Functional evidence implicating S100P in prostate cancer progression.

Basu GD, Azorsa DO, Kiefer JA, Rojas AM, Tuzmen S, Barrett MT, Trent JM, Kallioniemi O, Mousses S. Basu GD, et al. Among authors: tuzmen s. Int J Cancer. 2008 Jul 15;123(2):330-339. doi: 10.1002/ijc.23447. Int J Cancer. 2008. PMID: 18452169 Free article.

3

Validation of short interfering RNA knockdowns by quantitative real-time PCR.

Tuzmen S, Kiefer J, Mousses S. Tuzmen S, et al. Methods Mol Biol. 2007;353:177-203. doi: 10.1385/1-59745-229-7:177. Methods Mol Biol. 2007. PMID: 17332642

4

Site-directed mutagenesis.

Carrigan PE, Ballar P, Tuzmen S. Carrigan PE, et al. Among authors: tuzmen s. Methods Mol Biol. 2011;700:107-24. doi: 10.1007/978-1-61737-954-3_8. Methods Mol Biol. 2011. PMID: 21204030

5

Intersex-like (IXL) is a cell survival regulator in pancreatic cancer with 19q13 amplification.

Kuuselo R, Savinainen K, Azorsa DO, Basu GD, Karhu R, Tuzmen S, Mousses S, Kallioniemi A. Kuuselo R, et al. Among authors: tuzmen s. Cancer Res. 2007 Mar 1;67(5):1943-9. doi: 10.1158/0008-5472.CAN-06-3387. Cancer Res. 2007. PMID: 17332321

6

RNAi-based functional pharmacogenomics.

Tuzmen S, Tuzmen P, Arora S, Mousses S, Azorsa D. Tuzmen S, et al. Among authors: tuzmen p. Methods Mol Biol. 2011;700:271-90. doi: 10.1007/978-1-61737-954-3_18. Methods Mol Biol. 2011. PMID: 21204040

7

Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer.

Huusko P, Ponciano-Jackson D, Wolf M, Kiefer JA, Azorsa DO, Tuzmen S, Weaver D, Robbins C, Moses T, Allinen M, Hautaniemi S, Chen Y, Elkahloun A, Basik M, Bova GS, Bubendorf L, Lugli A, Sauter G, Schleutker J, Ozcelik H, Elowe S, Pawson T, Trent JM, Carpten JD, Kallioniemi OP, Mousses S. Huusko P, et al. Among authors: tuzmen s. Nat Genet. 2004 Sep;36(9):979-83. doi: 10.1038/ng1408. Epub 2004 Aug 8. Nat Genet. 2004. PMID: 15300251

8

Differential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtypes.

Gökmen-Polar Y, Mehta R, Tuzmen S, Mousses S, Thorat MA, Sanders KL, Turbin D, Leung S, Huntsman DG, Sledge GW Jr, Badve S. Gökmen-Polar Y, et al. Among authors: tuzmen s. Breast Cancer Res Treat. 2010 Nov;124(2):327-35. doi: 10.1007/s10549-010-0733-2. Epub 2010 Jan 23. Breast Cancer Res Treat. 2010. PMID: 20099025

9

An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer.

Mamo A, Cavallone L, Tuzmen S, Chabot C, Ferrario C, Hassan S, Edgren H, Kallioniemi O, Aleynikova O, Przybytkowski E, Malcolm K, Mousses S, Tonin PN, Basik M. Mamo A, et al. Among authors: tuzmen s. Oncogene. 2012 Apr 19;31(16):2090-100. doi: 10.1038/onc.2011.386. Epub 2011 Sep 5. Oncogene. 2012. PMID: 21892209

10

Update on the clinical utility of an RNA interference-based treatment: focus on Patisiran.

Rizk M, Tüzmen Ş. Rizk M, et al. Among authors: tuzmen s. Pharmgenomics Pers Med. 2017 Nov 10;10:267-278. doi: 10.2147/PGPM.S87945. eCollection 2017. Pharmgenomics Pers Med. 2017. PMID: 29184431 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

26 results

Search Page